Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD(2) antibody ch14.18/CHO

Immunotherapy with short term infusion (STI) of monoclonal anti-GD(2) antibody (mAb) ch14.18 (4 × 25 mg/m(2)/d; 8–20 h) in combination with cytokines and 13-cis retinoic acid (RA) prolonged survival in high-risk neuroblastoma (NB) patients. Here, we investigated long-term infusion (LTI) of ch14.18 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Mueller, Ina, Ehlert, Karoline, Endres, Stefanie, Pill, Lena, Siebert, Nikolai, Kietz, Silke, Brock, Penelope, Garaventa, Alberto, Valteau-Couanet, Dominique, Janzek, Evelyne, Hosten, Norbert, Zinke, Andreas, Barthlen, Winfried, Varol, Emine, Loibner, Hans, Ladenstein, Ruth, Lode, Holger N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800385/
https://www.ncbi.nlm.nih.gov/pubmed/29120699
http://dx.doi.org/10.1080/19420862.2017.1402997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800385/
https://www.ncbi.nlm.nih.gov/pubmed/29120699
http://dx.doi.org/10.1080/19420862.2017.1402997

Ejemplares similares